Interest in psychedelic medicine for traumatic brain injury has accelerated rapidly in recent years, with ibogaine and psilocybin emerging as two of the most promising compounds under investigation. Although research remains in its early stages, the findings reported to date have generated considerable excitement, raising the possibility that psychedelic medicines could fundamentally reshape how we approach recovery after brain injury.

A fascinating new case series has added to the growing conversation around psychedelics and brain injury recovery. The study explored the effects of an integrative iboga microdosing protocol in three individuals living with persistent symptoms following brain injury. The participants included two individuals with traumatic brain injury (TBI) and one individual with a chronic hypoxic brain injury.

Emerging evidence in individuals with traumatic brain injury suggests psychedelics may drive meaningful improvements in cognition, mood, and trauma — signalling a potential paradigm shift in neurorehabilitation.

I’ve conducted an independently led study exploring the effects of psychedelics on individuals living with brain injury. The findings highlight three key areas: reductions in trauma-related distress and greater emotional stability, a temporary post-dose “cognitive lift” in memory, clarity, and coordination, and deeper insight, acceptance, and self-compassion in relation to life after injury. In a field where treatment options remain limited, these outcomes point toward a therapeutic direction that is beginning to gain attention.